Expertise in
136
conditions

Dr. Joyce Teng

Pediatrics
Lucille Packard Children's Hospital 030962
770 Welch Rd, 
Palo Alto, CA 
Offers Telehealth
Referral may be required
Expertise in
136
conditions
Lucille Packard Children's Hospital 030962
770 Welch Rd, 
Palo Alto, CA 

Overview

Joyce Teng is a Pediatrics provider practicing medicine in Palo Alto, California.

Dr. Teng is highly rated in 136 conditions, according to our data. Her clinical expertise encompasses Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, Nevoid Basal Cell Carcinoma Syndrome, Fetal Retinoid Syndrome, and Liver Embolization.

She is actively involved in clinical research, co-authoring 119 peer reviewed articles and participating in 11 clinical trials.

Specialties

Pediatrics

Licenses

Dermatology in CA

Hospital Affiliations

Lucile Salter Packard Children's Hsp At Stanford

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 17 Less Insurance Carriers -

Locations

Lucille Packard Children's Hospital 030962
770 Welch Rd, Palo Alto, CA 94304
Other Locations
Lucile Packard Children's Hospital Stanford
725 Welch Rd, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Teng has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM)
Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM)
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Drug
Study Phase: Phase 2
Managed Access Programs for BYL719, Alpelisib
Managed Access Programs for BYL719, Alpelisib
Enrollment Status: Available
Publish Date: April 14, 2026
Intervention Type: Drug
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
Enrollment Status: Completed
Publish Date: September 11, 2023
Intervention Type: Drug
Study Drug: TolaSure
Study Phase: Phase 1
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Enrollment Status: Terminated
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: VT30
Study Phase: Phase 1/Phase 2
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Drug
Study Drugs: Sirolimus, Vehicle
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

119 Total Publications

Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors.
Subclonal IDH1/2 Mutations as a Targetable Vulnerability in Vascular Tumors.
Journal: bioRxiv : the preprint server for biology
Published: May 25, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Scott Lambert
Pediatrics
Expertise in
39
conditions
Dr. Scott Lambert
Pediatrics
Referral may be required

Comprehensive Ophthalmology And Optometry

2452 Watson Ct, 
Palo Alto, CA 
 (3.1 miles away)
650-723-1143
Languages Spoken:
English
See accepted insurances

Scott Lambert is a Pediatrics provider practicing medicine in Palo Alto, California. Dr. Lambert is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Congenital Cataract, Strabismus, Cataract, Cataract Removal, and Vitrectomy.

Expertise in
52
conditions
Dr. Gregory M. Enns
Pediatrics | Medical Genetics
Expertise in
52
conditions
Dr. Gregory M. Enns
Pediatrics | Medical Genetics
Referral may be required

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-498-7200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Enns is a Pediatrics specialist and a Medical Genetics provider practicing medicine in Palo Alto, California. Dr. Enns is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Urea Cycle Disorders (UCD), Methylmalonic Acidemia, Arginase Deficiency, and Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency. Dr. Enns is currently accepting new patients.

Expertise in
43
conditions
Dr. Dawn Siegel
Pediatrics
Expertise in
43
conditions
Dr. Dawn Siegel
Pediatrics
Referral may be required

Child And Adolescent Mental Health-Stanford Children's Health Specialty Services-Sunnyvale

1195 W Fremont Ave, 
Sunnyvale, CA 
 (8.5 miles away)
650-721-1227
Languages Spoken:
English
See accepted insurances

Dawn Siegel is a Pediatrics provider practicing medicine in Sunnyvale, California. Dr. Siegel is highly rated in 43 conditions, according to our data. Her clinical expertise encompasses PHACE Syndrome, Hemangioma, Aplasia Cutis Congenita, and Ectodermal Dysplasias.

Frequently Asked Questions about Dr. Joyce Teng

How do I make an appointment with Dr. Joyce Teng?

You can book an appointment with Dr. Joyce Teng by calling their office at 650-721-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joyce Teng a top-rated expert for Dowling-Meara Epidermolysis Bullosa Simplex?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joyce Teng is classified as an Elite expert for Dowling-Meara Epidermolysis Bullosa Simplex, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joyce Teng specialize in?

While Dr. Joyce Teng is a Pediatrics, they have specific expertise in Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, and Nevoid Basal Cell Carcinoma Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Joyce Teng participate in research or clinical trials?

Yes. Dr. Joyce Teng has published 119 articles and abstracts on conditions like Dowling-Meara Epidermolysis Bullosa Simplex. You can view a list of Dr. Joyce Teng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joyce Teng accept my insurance?

Dr. Joyce Teng accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 650-721-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Teng's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 123 Advanced Conditions
View All 135 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile